Valiant Navion 支架系统一年临床试验结局与胸主动脉形态分析
前瞻性单臂试验纳入100例胸主动脉瘤患者,评估Valiant Navion支架系统1年结局。全因死亡免除率89.8%、动脉瘤相关死亡免除率97.0%、二次手术免除率94.8%;远端主动脉伸长和扩张更明显,强调远端锚定区规划的重要性。
要点
- 1年全因死亡免除率89.8%,动脉瘤相关死亡免除率97.0%。
- 9例出现内漏,其中Ia型2例、Ib型4例、II型4例(部分重叠)。
- 远端主动脉重塑更明显,平均长度增加4.2mm、直径增加2.8mm。
核心结论
- 1年结局积极,死亡、内漏和二次手术免除率较高。
- 主动脉伸长和扩张在远端更常见,术前规划应重视远端锚定区。
- 主动脉重塑将持续,需进一步随访评估对支架性能的影响。
研究设计与样本
- 前瞻性单臂临床试验,纳入100例接受Valiant Navion支架系统的患者。
- 独立核心实验室评估解剖特征和性能结局。
主要发现
- 1年全因死亡免除率89.8%,动脉瘤相关死亡免除率97.0%,二次手术免除率94.8%。
- 5例患者共接受6次二次手术,9例出现内漏:Ia和Ib型1例、Ia型1例、Ib型3例、II型4例。
- 76例随访患者中,2例(2.6%)最大动脉瘤直径增加≥5mm,62例(81.6%)瘤囊稳定,12例(15.8%)瘤囊缩小。
- 近端锚定区短36例(36%),远端锚定区短31例(31%)。
- 近端主动脉平均伸长1.2mm、扩张1.6mm;远端平均伸长4.2mm、扩张2.8mm。
关键数值与推荐
- 术前胸主动脉迂曲度1.45±0.02,术后1个月1.46±0.02,术后1年自然增至1.49±0.02。
- 无部署失败;近端和远端锚定区短的定义见原文。
临床怎么用
- TEVAR规划时应充分考虑远端锚定区,因远端主动脉重塑更明显。
- 术后需长期影像随访监测主动脉形态变化及支架性能。
局限性
- 器械已于2021年2月17日全球召回,因3例支架断裂(2例确认IIIb型内漏)。
- 本系列100例手术在1年时无与召回原因相关的事件。
- 数据收集和分析在召回通知前完成,作者和制造商当时不知晓近期不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AUTHORS' NOTE: On February 17, 2021, Medtronic Incorporated issued a global voluntary recall of the Valiant Navion Thoracic Stent Graft System (the device under study in the Valiant Evo Global Clinical Program that is the subject of this publication), and instructed physicians to immediately cease use of the Valiant Navion system and return any unused product. Medtronic initiated the recall in response to three clinical trial subjects recently observed with stent fractures, two of whom have confirmed type IIIb endoleaks. The data collection, analysis, and manuscript submission occurred before the notice of this recall, and, specifically, the 100 procedures reviewed for this series were free of events at 1 year related to the reason for this device recall. The authors of this article and the manufacturer were unaware of the recently detected adverse events at the time of the preparation of the manuscript, and the 1-year trial results, and imaging-based analyses described are unchanged. Management of thoracic aortic aneurysms continues to be a challenging problem and outcomes are dependent on patient anatomy. The present publication focuses on the importance of achieving proximal and distal seals and the consideration of the temporal changes of the aortic morphology as a part of the TEVAR planning process. The authors believe there is still scientific merit in disclosing this information, despite the current nonavailability of the Valiant Navion system. OBJECTIVE: The Valiant Navion stent graft system (Medtronic Inc, Santa Rosa, Calif) is a third-generation device with improved conformability. We have reported the 1-year clinical trial outcomes, with a focus on an imaging-based analysis of the aortic morphology. We assessed the effects of graft implantation on the native anatomy and the effects of the 1-year changes in thoracic aorta morphology on the original seal zones of the stent graft. METHODS: A total of 100 subjects were enrolled in a prospective single-arm clinical trial investigating the Valiant Navion stent graft system. An independent core laboratory (Syntactx, New York, NY) assessed the anatomic characteristics and performance outcomes. RESULTS: Through 1 year of follow-up, the freedom from all-cause mortality, aneurysm-related mortality, and secondary procedures was 89.8%, 97.0%, and 94.8% respectively. Of the 100 patients, 5 had undergone a total of six secondary procedures, and 9 patients had developed an endoleak (type Ia and Ib in 1, type Ia in 1, type Ib in 3, and type II in 4 patients) within the first year. After 1 year, 2 of 76 patients (2.6%) had had an increase in their maximum aneurysm diameter of ≥5 mm, 62 (81.6%) had had stable sacs, and 12 (15.8%) had experienced sac shrinkage. Although no deployment failures had occurred, 36 of the 100 proximal (36%) and 31 of the 100 distal (31%) attachment zones were considered short according to our definitions. The stent graft had conformed to the native anatomy at implantation, because the preprocedural thoracic aorta tortuosity (1.45 ± 0.02) had not significantly changed at 1 month after implantation (1.46 ± 0.02). Despite a natural increase in thoracic tortuosity after 1 year (1.49 ± 0.02), wall apposition had been maintained over time, as evidenced by the low endoleak rates. Aortic elongation and dilation had occurred at the proximal end of the graft by an average of 1.2 mm and 1.6 mm, respectively. Aortic remodeling was more pronounced at the distal end, with an average increase of 4.2 mm in length and 2.8 mm in diameter. CONCLUSIONS: The included patients had had positive 1-year outcomes with high freedom from mortality, endoleak development, and secondary procedures. Aortic elongation and dilation were more prevalent at the distal end, emphasizing the importance of distal attachment zone consideration as part of preoperative planning. Because aortic remodeling can be expected to continue over time, additional follow-up and imaging analysis in the trial will be necessary to assess the aortic morphology and its effects on stent graft performance.
引用
- Verzini F, Desai N, Arko FR, et al. Clinical trial outcomes and thoracic aortic morphometry after one year with the Valiant Navion stent graft system. J Vasc Surg. 2021. PMID: 33592295. doi:10.1016/j.jvs.2021.01.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。